Observational study of SBRT for patients with rare tumors and oligometastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational study investigates the effectiveness and safety of stereotactic body radiation therapy (SBRT) in managing oligometastases from rare tumors. It aims to identify differences in treatment efficacy and toxicity across various cancer types, providing valuable insights into SBRT's role in these contexts. The study includes patients with a limited number of metastases and evaluates the potential for improved treatment outcomes through localized radiation therapy. By focusing on rare tumors, this research seeks to enhance treatment options for patients who often face limited choices.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ECOG PS 0 - 2
* histologically confirmed diagnosis of rare solid tumors including melanoma, soft tissue sarcoma, head-neck tumors, gynaecological tumors, Merkel cell carcinoma, thymic carcinoma, gastrointestinal stromal tumors (GIST) and urothelial tumors
* No limit to the number of metastases treated with SBRT but all active lesions must be treated with radical intent (primary tumor and metastases)
* Synchronous and metachronous oligometastases, as well as oligorecurrent and oligoprogressive disease are allowed
* Ablative dose intended as a minimum dose of 50Gy EQD2/10 in a maximum of 10 fractions
* No restrictions to prior or on-going systemic therapies

Exclusion Criteria:

* prior treatment with radiation to the same metastatic site
* inability to provide informed consent
* contraindications to SBRT

Where it's running

• Humanitas Research Hospital
  Rozzano, Milan, Italy Recruiting

Study contacts

• Study coordinator: Marta MD Scorsetti
• Email: marta.scorsetti@hunimed.eu
• Phone: + 39 02 8224 7454

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Immediate simulation-free SBRT for people with up to five metastatic tumors

  This tests whether giving stereotactic body radiation therapy (SBRT) right away without a separate CT simulation helps people with up to five metastatic cancer spots get treatment faster.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT07079098

• Stereotactic ablative radiotherapy versus single‑fraction palliative radiotherapy for oligoprogressive metastatic cancer

  This trial will test whether stereotactic ablative radiotherapy (SABR) works better than single‑fraction palliative radiotherapy (8 Gy) for people with 1–5 oligoprogressive metastatic lesions to delay the need for next‑line systemic therapy and improve quality of life.

  Recruiting British Columbia Cancer Agency · Surrey, British Columbia · NCT06918951

• Chemoimmunotherapy followed by surgery for limited spread esophageal and gastric cancer

  This study is testing if a combination of chemotherapy, immunotherapy, and surgery can help people with a limited spread of esophageal or gastric cancer live longer and have fewer recurrences.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT06668454

• Combining radiotherapy with systemic therapy for oligometastatic ureter cancer

  This study tests if adding radiotherapy to standard treatment can help people with a limited number of metastatic ureter cancer spots feel better and live longer.

  Recruiting at 2 sites Peking University First Hospital · Beijing and 1 other locations · NCT06652022

• Stereotactic radiotherapy for patients with oligometastatic cancer

  This study tests whether a special type of targeted radiation therapy can help people with a few metastatic tumors feel better compared to standard care after chemotherapy.

  Recruiting Phase 2/3 National Medical Research Radiological Centre of the Ministry of Health of Russia · Obninsk, Kaluga Oblast · NCT06556550

• Single‑fraction versus multiple‑fraction SBRT for treating limited metastases (SPRINT)

  This trial will test whether a single high‑dose SBRT treatment works as safely and effectively as multiple smaller SBRT treatments for people with limited metastases from breast, prostate, lung, or colorectal cancer.

  Recruiting at 2 sites European Organisation for Research and Treatment of Cancer - EORTC · Aalst and 14 other locations · NCT06462963

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.